Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Raj Ramaswamy who wrote (15747)	2/27/2006 9:19:02 PM
From: Galirayo	Respond to of 23958

>>You must be kidding...biotech with blockbuster drugs on fastrack always have expenses (trials, R&D etc). So forget the 'earnings'..there is none..what would you expect ? !<< Ill take that as a yes. Thanks .. I was curious after they tried to ruin the chart AH. stockcharts.com The analysts have been over exuberant recently anyway. Biotech company Nuvelo Inc. of San Carlos, Calif., said its fourth-quarter loss widened by nearly 61 percent, 2 cents more than analysts expected, sending shares down 83 cents, or 4.6 percent, to $17.43 on INET, from Monday's closing price of $18.26 on the Nasdaq.